Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Rallybio CorporationNASDAQ: RLYB

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow growth accelerates

Q1 FY2026 investing cash flow of $17.9M rose 61.5% year over year, ahead of the +57.6% change in trailing-twelve-month investing cash flow. Sequentially, it rose 356.1% from the prior quarter.

Context

  • Investing cash flow amounted to 5509.1% of revenue in FY2025, up 243.1 pp from a year earlier.
  • Investing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +61.5% holds above the trailing-twelve-month pace of +57.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.9M+356.1% QoQ
Last fiscal yearDec 2025
$47.27M+41.1% YoY
LTMMar 2026
$54.09M+57.6% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.5%——
1 year+41.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
47.27M USD
Year-over-year change
+41.1%

Investing Cash Flow vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's LTM Mar 2026 investing cash flow of $54.09M is the largest of the 4 companies compared; the peer median is $7M.
  • Its year-over-year change of +57.6% is the 2nd highest of 4, against a peer median of -64.7%.
  • Investing cash flow amounts to 6303.8% of revenue for RLYB, versus a peer median of 16006.0%.
RLYB Competitors Peer median
Investing Cash Flow for RLYB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLYBRallybio CorporationLTM Mar 2026$54.09M +57.6%—6303.8%
BOLDBoundless Bio, Inc.LTM Mar 2026$49.33M +219.8%+32.8%—
IBIOiBio, Inc.LTM Jun 2026$32M -4412.5%—31999.0%
QTTBQ32 Bio Inc.LTM Mar 2026$7M -64.7%—13.0%
Peer median (excluding RLYB) $7M-64.7%+32.8%16006.0%

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.01M)(66.65M)(74.56M)(57.78M)(8.98M)
Depreciation & Amortization109K167K150K131K92K
Deferred Income Tax00000
Stock-Based Compensation3.65M9.5M10.92M7.99M5.31M
Change in Working Capital(3.78M)(936K)4.28M(258K)(4.19M)
Accounts Receivables00000
Inventory00000
Accounts Payables(976K)487K(99K)(698K)(152K)
Other Working Capital(2.8M)(1.42M)4.38M440K(4.04M)
Other Non-Cash Items1.51M640K(1.05M)627K(22.05M)
Operating Cash Flow(45.53M)(57.28M)(60.27M)(49.28M)(29.81M)
Capital Expenditures(333K)(54K)(12K)00
Acquisitions (Net)(2M)(300K)(2.25M)(2M)0
Purchases of Investments(2M)(201.32M)(110.66M)(48.93M)(17.7M)
Sales of Investments2M89.5M138.33M84.43M46.47M
Other Investing Activities(2K)02.25M018.5M
Investing Cash Flow(2.33M)(112.17M)27.66M33.49M47.27M
Debt Repayment00000
Common Stock Issued86.2M51.53M143K5.41M16K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)(455K)0(206K)0
Financing Cash Flow82.97M51.08M143K5.2M16K
Effect of Forex Changes00000
Net Change in Cash35.1M(118.38M)(32.46M)(10.59M)17.47M
Free Cash Flow(45.87M)(57.34M)(60.28M)(49.28M)(29.81M)

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.